Contralateral prophylactic mastectomy and its association with reduced mortality: evidence for selection bias

Breast Cancer Research and Treatment

Volumn 148, Issue 2, 2014, Pages 389-396

  Jatoi, Ismail ^a   Parsons, Helen M ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Breast cancer; Contralateral prophylactic mastectomy; Mortality

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CLINICAL EFFECTIVENESS; CONTRALATERAL PROPHYLACTIC MASTECTOMY; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MASTECTOMY; OUTCOME ASSESSMENT; PREDICTIVE VALUE; SELECTION BIAS; SURVIVAL PREDICTION; SURVIVAL TIME; ADOLESCENT; BREAST NEOPLASMS; CANCER GRADING; CANCER REGISTRY; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; COMPARATIVE STUDY; ENZYME IMMUNOASSAY; FOLLOW UP; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STATISTICAL MODEL; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY; YOUNG ADULT;

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; LOGISTIC MODELS; MASTECTOMY; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEER PROGRAM; SELECTION BIAS; SURVIVAL RATE; YOUNG ADULT;

EID: 84911963073     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3160-y     Document Type: Article

References (29)

1. Kurian AW, Lichtensztajn DY, Keegan TH, Nelson DO, Clarke CA, Gomez SL (2014) Use of and mortality after bilateral mastectomy compared with other surgical treatments for breast cancer in California, 1998-2011. JAMA 312(9):902–914
2. Tuttle TM, Habermann EB, Grund EH, Morris TJ, Virnig BA (2007) Increasing use of contralateral prophylactic mastectomy for breast cancer patients: a trend toward more aggressive surgical treatment. J Clin Oncol 25(33):5203–5209
3. Neuburger J, Macneill F, Jeevan R, van der Meulen JH, Cromwell DA (2013) Trends in the use of bilateral mastectomy in England from 2002 to 2011: retrospective analysis of hospital episode statistics. BMJ Open 3(8). doi:10.1136/bmjopen-2013-003179
4. Musiello T, Bornhammar E, Saunders C (2013) Breast surgeons’ perceptions and attitudes towards contralateral prophylactic mastectomy. ANZ J Surg 83(7–8):527–532
5. Sim Y, Tan VK, Ho GH, Wong CY, Madhukumar P, Tan BK et al (2014) Contralateral prophylactic mastectomy in an Asian population: a single institution review. Breast 23(1):56–62
6. Yao K, Stewart AK, Winchester DJ, Winchester DP (2010) Trends in contralateral prophylactic mastectomy for unilateral cancer: a report from the National Cancer Data Base, 1998-2007. Ann Surg Oncol 17(10):2554–2562
7. Peralta EA, Ellenhorn JD, Wagman LD, Dagis A, Andersen JS, Chu DZ (2000) Contralateral prophylactic mastectomy improves the outcome of selected patients undergoing mastectomy for breast cancer. Am J Surg 180(6):439–445
8. Herrinton LJ, Barlow WE, Yu O, Geiger AM, Elmore JG, Barton MB et al (2005) Efficacy of prophylactic mastectomy in women with unilateral breast cancer: a cancer research network project. J Clin Oncol 23(19):4275–4286
9. Bedrosian I, Hu CY, Chang GJ (2010) Population-based study of contralateral prophylactic mastectomy and survival outcomes of breast cancer patients. J Natl Cancer Inst 102(6):401–409
10. Boughey JC, Hoskin TL, Degnim AC, Sellers TA, Johnson JL, Kasner MJ et al (2010) Contralateral prophylactic mastectomy is associated with a survival advantage in high-risk women with a personal history of breast cancer. Ann Surg Oncol 17(10):2702–2709
11. Brewster AM, Bedrosian I, Parker PA, Dong W, Peterson SK, Cantor SB et al (2012) Association between contralateral prophylactic mastectomy and breast cancer outcomes by hormone receptor status. Cancer 118(22):5637–5643
12. Evans DG, Ingham SL, Baildam A, Ross GL, Lalloo F, Buchan I et al (2013) Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Res Treat 140(1):135–142
13. Metcalfe K, Gershman S, Ghadirian P, Lynch HT, Snyder C, Tung N et al (2014) Contralateral mastectomy and survival after breast cancer in carriers of BRCA1 and BRCA2 mutations: retrospective analysis. BMJ 348:g226
14. Grimes DA, Schulz KF (2002) Bias and causal associations in observational research. Lancet 359(9302):248–252
15. Institute nc. surveillance epidemiology and end results program (2014) Available from: http://seer.cancer.gov/. Accessed 29 April 2014
16. Janschek E, Kandioler-Eckersberger D, Ludwig C, Kappel S, Wolf B, Taucher S et al (2001) Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer. Breast Cancer Res Treat 67(1):1–8
17. Narod SA (2014) Bilateral breast cancers. Nat Rev Clin Oncol 11(3):157–166
18. Lizarraga IM, Sugg SL, Weigel RJ, Scott-Conner CE (2013) Review of risk factors for the development of contralateral breast cancer. Am J Surg 206(5):704–708
19. Murphy JA, Milner TD, O’Donoghue JM (2013) Contralateral risk-reducing mastectomy in sporadic breast cancer. Lancet Oncol 14(7):e262–e269
20. Jatoi I, Benson JR, Liau SS, Chen Y, Cisco RM, Norton JA et al (2010) The role of surgery in cancer prevention. Curr Probl Surg 47(10):750–830
21. King TA, Sakr R, Patil S, Gurevich I, Stempel M, Sampson M et al (2011) Clinical management factors contribute to the decision for contralateral prophylactic mastectomy. J Clin Oncol 29(16):2158–2164
22. Katz SJ, Morrow M (2013) Contralateral prophylactic mastectomy for breast cancer: addressing peace of mind. JAMA 310(8):793–794
23. Jatoi I, Benson JR (2013) The case against routine preoperative breast MRI. Future Oncol 9(3):347–353
24. Sorbero ME, Dick AW, Beckjord EB, Ahrendt G (2009) Diagnostic breast magnetic resonance imaging and contralateral prophylactic mastectomy. Ann Surg Oncol 16(6):1597–1605
25. Khan SA (2011) Contralateral prophylactic mastectomy: what do we know and what do our patients know? J Clin Oncol 29(16):2132–2135
26. Jatoi I, Benson JR (2014) Novel approaches to the diagnosis and treatment of breast cancer. Future Oncol 10(4):515–518
27. Grimes DA, Schulz KF (2012) False alarms and pseudo-epidemics: the limitations of observational epidemiology. Obstet Gynecol 120(4):920–927
28. Sackett DL (1979) Bias in analytic research. J Chronic Dis 32(1–2):51–63
29. Mamdani M, Sykora K, Li P, Normand SL, Streiner DL, Austin PC et al (2005) Reader’s guide to critical appraisal of cohort studies: 2. Assessing potential for confounding. BMJ 330(7497):960–962